Retinitis pigmentosa gene therapy - ID Pharma/Kyushu University

Drug Profile

Retinitis pigmentosa gene therapy - ID Pharma/Kyushu University

Alternative Names: DVC1-0401

Latest Information Update: 08 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ID Pharma; Kyushu University
  • Class Eye disorder therapies; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Retinitis pigmentosa

Most Recent Events

  • 08 Jul 2016 Clinical development is ongoing in Japan
  • 26 Mar 2013 Clinical trials in Retinitis pigmentosa in Japan (unspecified route)
  • 10 Nov 2010 Investigation in Retinitis pigmentosa in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top